Ascendiant Capital Markets Forecasts SXTP Q1 Earnings

60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) – Equities research analysts at Ascendiant Capital Markets issued their Q1 2026 EPS estimates for 60 Degrees Pharmaceuticals in a research report issued on Thursday, April 9th. Ascendiant Capital Markets analyst L. Ward expects that the company will post earnings per share of ($0.99) for the quarter. Ascendiant Capital Markets currently has a “Buy” rating and a $4.20 price target on the stock. The consensus estimate for 60 Degrees Pharmaceuticals’ current full-year earnings is ($5.09) per share. Ascendiant Capital Markets also issued estimates for 60 Degrees Pharmaceuticals’ Q2 2026 earnings at ($0.78) EPS, Q3 2026 earnings at ($0.79) EPS, Q4 2026 earnings at ($0.83) EPS and FY2026 earnings at ($3.18) EPS.

Several other equities research analysts have also commented on SXTP. Weiss Ratings reissued a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research note on Friday, March 27th. HC Wainwright raised their price objective on 60 Degrees Pharmaceuticals from $6.00 to $24.00 and gave the company a “buy” rating in a research note on Tuesday, January 27th. Finally, Wall Street Zen downgraded 60 Degrees Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $14.10.

60 Degrees Pharmaceuticals Trading Down 11.7%

Shares of 60 Degrees Pharmaceuticals stock opened at $1.96 on Wednesday. The company has a 50-day moving average of $2.50 and a two-hundred day moving average of $3.62. 60 Degrees Pharmaceuticals has a 12-month low of $1.29 and a 12-month high of $17.68. The stock has a market cap of $5.17 million, a PE ratio of -0.14 and a beta of 3.27.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.